Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference
02:32pm, Wednesday, 08'th Jun 2022
Media Release COPENHAGEN, Denmark ; June 8 , 20 2 2 Genmab A/S (Nasdaq: GMAB ) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will parti
Genmab A/S (GMAB) Q1 2022 Earnings Call Transcript
01:30am, Thursday, 12'th May 2022 The Motley Fool
GMAB earnings call for the period ending March 31, 2022.
Genmab A/S (GMAB) CEO Jan van de Winkel on Q1 2022 Results - Earning Call Transcript
06:08pm, Wednesday, 11'th May 2022
Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Confe
Should You Buy Genmab (GMAB) Ahead of Earnings?
02:35pm, Tuesday, 10'th May 2022 Zacks Investment Research
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Genmab (GMAB) Ahead of Earnings?
12:03pm, Tuesday, 10'th May 2022
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
02:02pm, Monday, 02'nd May 2022 Benzinga
Upgrades
For First Interstate BancSystem Inc (NASDAQ:FIBK), Keefe, Bruyette & Woods upgraded the previous rating of Market Perform to Outperform. For the first quarter, First Interstate BancSys had an
3 Things About BioNTech That Smart Investors Know
10:18am, Friday, 29'th Apr 2022 The Motley Fool
It's unlikely to be a one-hit wonder. And that should be great for patient investors.
Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
02:01pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate o
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer-BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Ages 5-11
Pfizer Inc (
Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties
12:27pm, Friday, 08'th Apr 2022
Johnson & Johnson's (NYSE: JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ: GMAB) on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab). Th
Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets
02:07pm, Friday, 18'th Mar 2022 Zacks Investment Research
Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.
Genmab: A Biotech Company On The Rise
04:00pm, Saturday, 12'th Mar 2022
Genmab enjoyed a strong 2021, recording revenues that have been able to maintain the majority of the growth seen in 2020.
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
02:19pm, Wednesday, 09'th Mar 2022 Zacks Investment Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
10:32am, Wednesday, 09'th Mar 2022
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for
AbbVie-partnered blood cancer candidate granted FDA’s orphan drug status
12:56pm, Tuesday, 08'th Mar 2022 Seeking Alpha
Danish biotech, Genmab (GMAB) announced on Tuesday that the U.S FDA ranted the orphan-drug designation to Epcoritamab. Read more.
